Share on

Middle East & Africa Overactive Bladder Treatment Market Research Report - Segmented By Treatment, Disease & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2023 to 2028)

Published: March, 2023
ID: 7590
Pages: 145
Formats: report pdf report excel report power bi report ppt

MEA Overactive Bladder Treatment Market Size & Growth (2023 to 2028)

As per the research report, the size of the Middle East and Africa Overactive Bladder Treatment Market is valued at USD 0.51 billion in 2023 and is projected to grow at a CAGR of 2.55%, to reach USD 0.58 billion by 2028 during the forecast period 2023 to 2028.

The growing patient population of overactive bladder across the Middle East Africa region majorly drives the growth of the MEA overactive bladder treatment market. A substantial portion of women aged 39 years and above are affected by overactive bladder issues, characterized by sudden and frequent urges to urinate that can be challenging to control throughout the day and night. Various factors contribute to the development of an overactive bladder, including abdominal trauma, infections, nerve damage, medications, and lifestyle factors such as dietary changes, alcohol consumption, and obesity. Post-pregnancy, many women also experience overactive bladder symptoms, further contributing to the market demand. Healthcare providers employ diagnostic tests such as urinalysis, urodynamic testing, ultrasound, computer tomography scan, and cystoscopy to diagnose overactive bladder conditions.

The growing geriatric population and rising awareness about available treatments further boost the growth rate of the MEA overactive bladder treatment market. The risk of developing an overactive bladder increases with age, and conditions such as enlarged prostate and diabetes can further affect bladder function. Neurological conditions such as Alzheimer's disease and stroke are also associated with overactive bladder issues. Management of these issues often involves dietary changes and medications prescribed by skilled healthcare professionals.

High incidence of comorbid conditions like enlarged prostate and diabetes, increasing demand for effective management of overactive bladder symptoms in neurological conditions such as Alzheimer's disease and stroke and the development of novel treatments and therapies for overactive bladder promotes the growth of the overactive bladder treatment market in MEA. The growing investment in research and development activities, supportive initiatives and funding from healthcare organizations and the expansion of drug approvals for overactive bladder treatment favours the regional market growth.

Limited awareness about overactive bladder treatment, product recalls, social stigma, availability of alternative therapies, lack of skilled professionals and limited availability of drugs primarily hamper the growth of the MEA overactive bladder treatment market. Side effects associated with certain medications further impede the growth of the MEA market.

This research report on the Middle East & Africa Overactive Bladder Treatment Market has been segmented and sub-segmented into the following categories:

By Treatment:

  • Mirabegron
  • Anticholinergics
  • Botox
  • Intravesical Instillation
  • Neurostimulation

By Disease:

  • Neurogenic Overactive Bladder
  • Idiopathic Overactive Bladder

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

The Middle East and Africa region accounted for a moderate share of the global market in 2023. However, the regional market is anticipated to account for a considerable share of the worldwide market during the forecast period owing to the advancements in the healthcare sector and increased healthcare expenditure. Saudi Arabia is expected to hold the leading share of the MEA market in the coming years owing to the growing incidence of overactive bladder cases among women that impact workplace productivity and daily routines.

KEY MARKET PLAYERS:

The leading companies leading in the MEA Overactive Bladder Treatment Market profiled in the report are Pfizer, Allergan Plc, Hisamitsu Pharmaceutical, Johnson & Johnson, Astellas Pharma Inc, Teva Pharmaceutical Industries, Mylan N.V, Sanofi, Aurobindo Pharma Ltd, and Endo International.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample